Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study Yasenchak, C. A., Halwani, A., Advani, R., Ansell, S., Budde, L., Burke, J. M., Farber, C. M., Holkova, B., Fayad, L. E., Kolibaba, K. S., Knapp, M., Li, M., Manley, T. J., Patel-Donnelly, D., Seetharam, M., Yimer, H. A., Bartlett, N. L. AMER SOC HEMATOLOGY. 2015
View details for Web of Science ID 000368019002251